⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
SGLT2 Inhibitors
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-11 — Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.: [human-rct — protocol only, no outcome results] HABIT-GEMs describes a multicentre, randomized, open-label non-inferiority trial comparing henagliflozin with metformin XR for preservation of appendicular skeletal muscle mass in adults aged 60–85 with newly diagnosed type 2 diabetes, without yet establishing muscle preservation or resolving existing lean-mass concerns. [human-rct] (novelty: 3)
- 2026-11-02 — Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.: [human-observational] A one-year matched observational cohort of prefrail older adults with hypertension and chronic kidney disease found dapagliflozin treatment associated with 87% lower odds of progression to frailty, not an established causal or absolute-risk reduction; this population-specific association contrasts with the existing null empagliflozin functional-capacity RCT but involves a different drug, population, and endpoint. [human-observational] (novelty: 3)
- 2026-03-07 — Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial.: [human-rct] The 180-day, double-blind randomized Empire Prevent Cardiac trial found no improvement in VO2 max, daily physical activity, or quality of life with empagliflozin in older adults with overweight or obesity and heart failure risk factors but without established diabetes or heart failure, providing no support for functional benefits in this population despite the page’s model-based aging rationale. [human-rct] (novelty: 3)
- 2026-10-26 — Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.: [expert-opinion] Review synthesizing trial and observational evidence reports SGLT2 inhibitor-associated lean-mass reductions proportional to weight loss without consistent strength or performance impairment, distinguishing lean-mass loss alone from sarcopenia while proposing functional monitoring and lifestyle countermeasures for vulnerable older adults; no new primary data establish safety or preventive efficacy in these populations. [expert-opinion] (novelty: 3)
- 2026-08-25 — Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m: A Target Trial Emulation.: [human-observational] Target trial emulation in adults with type 2 diabetes and BMI <27 kg/m² found lower heart failure risk associated with GLP-1 receptor agonist use than SGLT2 inhibitor use; this nonrandomized comparison does not establish causal superiority or show that SGLT2 inhibitors increase risk relative to usual care. [human-observational] (novelty: 3)
- 2026-11-01 — Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.: [human-observational] Active-comparator target trial emulation involving over 1.5 million matched adults with serious mental illness found lower all-cause mortality and major adverse cardiovascular event rates with GLP-1 receptor agonist initiation than SGLT2 inhibitor initiation; this nonrandomized comparison does not establish causal superiority or show that SGLT2 inhibitors increase risk relative to no treatment. [human-observational] (novelty: 3)
- 2026-10-09 — Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.: [human-observational] Retrospective comparative cohort in patients with type 2 diabetes and COPD found tirzepatide associated with lower all-cause mortality and fewer COPD exacerbations than SGLT2 inhibitors; this nonrandomized comparison does not establish causal superiority or show that SGLT2 inhibitors increase either risk relative to no treatment. [human-observational] (novelty: 3)
- 2026-10-06 — Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions.: Same 90-day Beagle intervention study included canagliflozin as a comparator arm and found a narrower exploratory cytokine response than rapamycin, with heterogeneous sex-stratified baselines — small exploratory canine signal, no outcome data. [animal-model] (novelty: 3)
- 2026-09-27 — Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.: Propensity-matched real-world CKD cohort found SGLT2i alone was outperformed by SGLT2i + GLP-1 RA on major adverse kidney events, MACE, and all-cause mortality, suggesting incremental benefit from adding incretin therapy on top of the SGLT2i backbone — observational only. [human-observational] (novelty: 3)
- 2026-08-01 — Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.: Narrative review on multi-organ cardiometabolic aging positions SGLT2 inhibitors (alongside RAAS blockade) as a nodal cardioprotective intervention acting on cross-organ senescence and oxidative-stress pathways rather than glycaemic control alone; framing only, no new trial data. [expert-opinion] (novelty: 3)
- 2026-08-01 — A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.: QSP aging model places SGLT2 inhibition in BOTH predicted optimal triple combinations (with GLP-1 RA + metformin for metabolic endpoints; with GLP-1 RA + rapamycin for aging-related states), suggesting a shared backbone role across objectives — simulation output, no direct longevity trial. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.
11-nov-2026
novelty 3
per-area 3
strengthens
Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.
02-nov-2026
novelty 3
per-area 3
strengthens
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.
01-nov-2026
novelty 3
per-area 3
strengthens
Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.
26-oct-2026
novelty 3
per-area 3
strengthens
Association between SGLT2 inhibitor use and functional outcomes in elderly patients receiving ferric carboxymaltose: a retrospective observational cohort study.
21-oct-2026
novelty 2
per-area 2
strengthens
Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework.
17-oct-2026
novelty 3
per-area 3
strengthens
Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.
09-oct-2026
novelty 3
per-area 3
strengthens
Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions.
06-oct-2026
novelty 3
per-area 3
strengthens
Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.
30-sep-2026
novelty 2
per-area 1
mentions
Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial.
29-sep-2026
novelty 2
per-area 2
mentions
Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.
27-sep-2026
novelty 3
per-area 3
strengthens
Trajectory-Oriented Brain Vulnerability Framework for Cognitive Decline in Type 2 Diabetes.
19-sep-2026
novelty 2
per-area 2
mentions
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026
novelty 2
per-area 2
strengthens
The Effect of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors Alone and in Combination on AF Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation.
17-sep-2026
novelty 2
per-area 2
strengthens
Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m: A Target Trial Emulation.
25-aug-2026
novelty 3
per-area 3
strengthens
The dual role of the cGAS-STING signaling pathway in kidney diseases: from acute injury to chronic fibrosis - molecular mechanisms and precision therapeutic strategies.
05-aug-2026
novelty 2
per-area 2
mentions
Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.
01-aug-2026
novelty 3
per-area 3
strengthens
A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
01-aug-2026
novelty 3
per-area 3
strengthens
Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.
16-jul-2026
novelty 2
per-area 3
strengthens
Divergent Risks of Endocrine and Nonendocrine Malignancies in GLP-1 Receptor Agonist Users: A Propensity-Matched Real-World Analysis of Over 140 000 Patients.
15-may-2026
novelty 3
per-area 1
mentions
Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial.
07-mar-2026
novelty 3
per-area 3
strengthens